Delivery Order SPE2DB25D3005-SPE2DB25FQHBD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,649.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes. This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,649 to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on August 5, 2025, with completion scheduled for August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a single pharmaceutical supply transaction within the company's broader federal contract portfolio. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Gel-One 30 mg/3 mL syringes with a ceiling value of $3,649.00 and an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,824.50 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitive contract award, which carries no set-aside designation, is structured as a firm fixed price delivery order. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a $18,245 delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on August 7, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The company, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $4,378.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a non-set-aside contract executed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle valued through December 2026. The place of performance is AmerisourceBergen's corporate...
- The U.S. Defense Logistics Agency (DLA) awarded a $7,054.40 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of 4565562938 - GEL-ONE 30 MG/3 ML SYRINGE 3ML, with a completion date of August 22, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that supplies essential medical commodities, including prescription drugs, vaccines, and medical supplies, to various federal agencies and healthcare...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for GEL-ONE 30 MG/3 ML SYRINGE 3ML. The potential value of this contract is $1,763.60 and the completion date is March 12, 2024. Amerisourcebergen Drug Corp provides a wide range of pharmaceutical products and medical supplies to U.S. government agencies, including the Department of Defense, through indefinite delivery...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML. The potential value of this order is $5,290.80, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor for this delivery order, which is not designated as a set-aside contract. This award is part of...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of global pharmaceutical distributor Amerisourcebergen Corporation. The $21,163.20 delivery order is for GEL-ONE 30 MG/3 ML SYRINGE 3ML, with an ultimate completion date of April 16, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary vehicle...
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB25FQHBDDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,649.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes. This competitive, firm fixed-price delivery order, issued on July 22, 2025, is scheduled for completion by August 12, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition to this established federal pharmaceutical vendor. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime contractor for this comprehensive global pharmaceutical support vehicle, AmerisourceBergen Drug Corp supplies a broad range of pharmaceutical products and medical commodities to support military healthcare programs. The company's extensive federal contract portfolio reflects its critical role in the Defense Health Agency's medical supply chain, delivering medications, vaccines, medical devices, and specialized supplies across multiple therapeutic domains to military and veteran healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/22/25 |